TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the fourth quarter and full year of 2006. The Company reported a net loss of $31.0 million, or $0.51 per share (basic and diluted), for the fourth quarter of 2006 compared with a net loss of $29.7 million, or $0.53 per share (basic and diluted), for the fourth quarter of 2005. The Company reported a net loss of $102.3 million, or $1.77 per share (basic and diluted), for the year ended December 31, 2006 compared with a net loss of $95.4 million, or $1.71 per share (basic and diluted), for the same period in 2005. Results for 2005 included other income of $30.6 million resulting from one-time, non-recurring payments of $25.0 million from the sanofi-aventis Group and $5.6 million from The Procter & Gamble Company in connection with amendments to the Company’s collaboration agreements with sanofi-aventis and Procter & Gamble.
